SELLAS Life Sciences Group, Inc. (SLS) stock
Close on Nov 12, 2026Market cap $1.62BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.62B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 12.30
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$35.76M
- EPS, diluted
- -$0.20
- Book value per share
- $0.65
- Diluted shares
- 202M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $8.42
- Open
- $8.16
- Day's range
- $8.00 – $8.40
- Volume
- 4,380,246
- Average volume (20 days)
- 7,761,465
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 1.49
- 52-week range
- $1.39 – $15.88
- RSI (14 days)
- 37.6
- Volatility (1 year)
- 109.6%
- Relative volume
- 0.57×
- WACC
- 12.4%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | SLS | S&P 500 | Difference | SLS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -32.7% | -2.7% | −30.0 pts | ||
| 3 months | -31.8% | -1.7% | −30.0 pts | ||
| Year to date | +113.0% | +11.9% | +101.1 pts | ||
| 1 year | +438.9% | +12.0% | +426.9 pts | ||
| 3 years | +784.6% | +78.2% | +706.4 pts | +106.8% | +21.2% |
| 5 years | +11.8% | +73.2% | −61.4 pts | +2.3% | +11.6% |
| 10 years | -99.9% | +309.6% | −409.5 pts | -48.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases SELLAS Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
About SELLAS Life Sciences
Pharmaceutical Preparations
The company is a late-stage clinical biopharmaceutical enterprise dedicated to developing innovative treatments for multiple cancer indications. Its development pipeline centers on two main product candidates: galinpepimut-S (GPS), a targeted peptide immunotherapy engineered against the WT1 antigen, and SLS009 (tambiciclib), a selective small molecule CDK9 inhibitor. The business evaluates these investigational therapies for hematologic malignancies such as acute myeloid leukemia, multiple myeloma, and lymphoma, as well as various solid tumors. Its ultimate prospective end-users are cancer patients requiring novel therapeutic interventions, while its operational partners include healthcare institutions, research networks, and biotechnology collaborators licensed for regional commercialization.
Company profile, executives and historySELLAS Life Sciences stock: common questions
What is SELLAS Life Sciences's stock price?
SLS closed at $8.03 on Nov 12, 2026, down 4.63% on the day. Over the past 52 weeks it traded between $1.39 and $15.88.
What is SELLAS Life Sciences's market cap?
SELLAS Life Sciences was worth $1.62B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is SLS's P/E ratio?
SELLAS Life Sciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.20), so it has no meaningful P/E ratio.
Does SELLAS Life Sciences pay a dividend?
No. SELLAS Life Sciences has not paid a cash dividend over the last twelve months.
When does SELLAS Life Sciences report earnings next?
SELLAS Life Sciences's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has SLS stock performed over the past year?
Including dividends, SLS returned +438.9% over the past year, against +12.0% for the S&P 500.
How many SLS shares are sold short?
57M shares were sold short at the latest FINRA report, 28.80% of the float, or 6.7 days of average trading volume.
Who are SELLAS Life Sciences's competitors?
Companies most similar to SELLAS Life Sciences by business, industry and size include CLRB, MBRX, IMNM, CBIO, AVBP.
See a number that looks wrong?